News
-
-
-
COMMUNIQUÉ DE PRESSE
Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 as monotherapy and in combination with immune checkpoint inhibitors at AACR
Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 at AACR, showcasing potential to enhance immune checkpoint inhibitors' efficacy -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
Secarna Pharmaceuticals presents ASO data targeting NLRP3 at Inflammasome Therapeutics Summit, showcasing potential in inflammatory disease treatment -
